ASX - By Stock
|
MSB |
Re:
Ann: Ischemic End Stage HF Outcomes at Virtual ACC Annual Meeting
|
|
otherperspective
|
84 |
34K |
78 |
31/03/20 |
31/03/20 |
ASX - By Stock
|
84
|
34K
|
78
|
|
ASX - By Stock
|
MSB |
Re:
The case for Mesoblast's MSCs for ARDS
|
|
otherperspective
|
221 |
90K |
68 |
25/03/20 |
25/03/20 |
ASX - By Stock
|
221
|
90K
|
68
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast owns the patents . The science is now proven .
|
|
otherperspective
|
47 |
23K |
33 |
19/03/20 |
19/03/20 |
ASX - By Stock
|
47
|
23K
|
33
|
|
ASX - By Stock
|
MSB |
Mesoblast owns the patents . The science is now proven .
|
|
otherperspective
|
47 |
23K |
68 |
19/03/20 |
19/03/20 |
ASX - By Stock
|
47
|
23K
|
68
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast to Evaluate Remestemcel-L in COVID-19 Lung Disease
|
|
otherperspective
|
443 |
200K |
71 |
18/03/20 |
18/03/20 |
ASX - By Stock
|
443
|
200K
|
71
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast to Evaluate Remestemcel-L in COVID-19 Lung Disease
|
|
otherperspective
|
443 |
200K |
86 |
10/03/20 |
10/03/20 |
ASX - By Stock
|
443
|
200K
|
86
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
otherperspective
|
23K |
13M |
37 |
09/03/20 |
09/03/20 |
ASX - By Stock
|
23K
|
13M
|
37
|
|
ASX - By Stock
|
MSB |
Re:
Coronavirus
|
|
otherperspective
|
39 |
1.2M |
46 |
03/03/20 |
03/03/20 |
ASX - By Stock
|
39
|
1.2M
|
46
|
|
ASX - By Stock
|
MSB |
Half Year Results- Conference Call
|
|
otherperspective
|
27 |
171K |
72 |
27/02/20 |
27/02/20 |
ASX - By Stock
|
27
|
171K
|
72
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Positive Outcomes Using Remestemcel-L in Chronic GVHD
|
|
otherperspective
|
53 |
82K |
80 |
20/02/20 |
20/02/20 |
ASX - By Stock
|
53
|
82K
|
80
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
otherperspective
|
23K |
13M |
61 |
17/02/20 |
17/02/20 |
ASX - By Stock
|
23K
|
13M
|
61
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
otherperspective
|
23K |
13M |
92 |
07/02/20 |
07/02/20 |
ASX - By Stock
|
23K
|
13M
|
92
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Appendix 4C - quarterly
|
|
otherperspective
|
135 |
88K |
51 |
30/01/20 |
30/01/20 |
ASX - By Stock
|
135
|
88K
|
51
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
otherperspective
|
18K |
6.9M |
17 |
28/01/20 |
28/01/20 |
ASX - By Stock
|
18K
|
6.9M
|
17
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
otherperspective
|
23K |
13M |
16 |
25/01/20 |
25/01/20 |
ASX - By Stock
|
23K
|
13M
|
16
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
otherperspective
|
23K |
13M |
85 |
25/01/20 |
25/01/20 |
ASX - By Stock
|
23K
|
13M
|
85
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
otherperspective
|
23K |
13M |
63 |
25/01/20 |
25/01/20 |
ASX - By Stock
|
23K
|
13M
|
63
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
otherperspective
|
23K |
13M |
99 |
23/01/20 |
23/01/20 |
ASX - By Stock
|
23K
|
13M
|
99
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
otherperspective
|
23K |
13M |
19 |
19/01/20 |
19/01/20 |
ASX - By Stock
|
23K
|
13M
|
19
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
otherperspective
|
23K |
13M |
93 |
18/01/20 |
18/01/20 |
ASX - By Stock
|
23K
|
13M
|
93
|
|
ASX - By Stock
|
MSB |
Re:
Ann: MSB Presents Commercial Plans at 2020 Biotech Showcase
|
|
otherperspective
|
48 |
27K |
44 |
15/01/20 |
15/01/20 |
ASX - By Stock
|
48
|
27K
|
44
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
otherperspective
|
23K |
13M |
76 |
10/01/20 |
10/01/20 |
ASX - By Stock
|
23K
|
13M
|
76
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
otherperspective
|
18K |
6.9M |
21 |
07/01/20 |
07/01/20 |
ASX - By Stock
|
18K
|
6.9M
|
21
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
otherperspective
|
23K |
13M |
46 |
06/01/20 |
06/01/20 |
ASX - By Stock
|
23K
|
13M
|
46
|
|
ASX - By Stock
|
MSB |
Re:
Ann: DMC Completes Final Review of Phase 3 Heart Failure Trial
|
|
otherperspective
|
73 |
49K |
48 |
04/01/20 |
04/01/20 |
ASX - By Stock
|
73
|
49K
|
48
|
|
ASX - By Stock
|
MSB |
Re:
Ann: DMC Completes Final Review of Phase 3 Heart Failure Trial
|
|
otherperspective
|
73 |
49K |
38 |
01/01/20 |
01/01/20 |
ASX - By Stock
|
73
|
49K
|
38
|
|
ASX - By Stock
|
MSB |
Re:
Ann: DMC Completes Final Review of Phase 3 Heart Failure Trial
|
|
otherperspective
|
73 |
49K |
59 |
31/12/19 |
31/12/19 |
ASX - By Stock
|
73
|
49K
|
59
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading - 2019
|
|
otherperspective
|
4.4K |
2.4M |
43 |
31/12/19 |
31/12/19 |
ASX - By Stock
|
4.4K
|
2.4M
|
43
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading - 2019
|
|
otherperspective
|
4.4K |
2.4M |
66 |
25/12/19 |
25/12/19 |
ASX - By Stock
|
4.4K
|
2.4M
|
66
|
|
ASX - By Stock
|
MSB |
Re:
Ann: DMC Completes Final Review of Phase 3 Heart Failure Trial
|
|
otherperspective
|
73 |
49K |
34 |
18/12/19 |
18/12/19 |
ASX - By Stock
|
73
|
49K
|
34
|
|
ASX - By Stock
|
MSB |
Re:
Ann: CHF P3Trial Accrues Sufficient Primary EndPt Events(Correct)
|
|
otherperspective
|
18 |
15K |
78 |
17/12/19 |
17/12/19 |
ASX - By Stock
|
18
|
15K
|
78
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading - 2019
|
|
otherperspective
|
4.4K |
2.4M |
38 |
10/12/19 |
10/12/19 |
ASX - By Stock
|
4.4K
|
2.4M
|
38
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
otherperspective
|
18K |
6.9M |
8 |
28/11/19 |
28/11/19 |
ASX - By Stock
|
18K
|
6.9M
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
otherperspective
|
18K |
6.9M |
24 |
28/11/19 |
28/11/19 |
ASX - By Stock
|
18K
|
6.9M
|
24
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Presentation to 2019 Annual General Meeting
|
|
otherperspective
|
36 |
17K |
19 |
27/11/19 |
27/11/19 |
ASX - By Stock
|
36
|
17K
|
19
|
|
ASX - By Stock
|
MSB |
Re:
MSB Investing
|
|
otherperspective
|
45 |
26K |
34 |
26/11/19 |
26/11/19 |
ASX - By Stock
|
45
|
26K
|
34
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
otherperspective
|
275 |
160K |
44 |
20/11/19 |
20/11/19 |
ASX - By Stock
|
275
|
160K
|
44
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading - 2019
|
|
otherperspective
|
4.4K |
2.4M |
20 |
04/11/19 |
04/11/19 |
ASX - By Stock
|
4.4K
|
2.4M
|
20
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading - 2019
|
|
otherperspective
|
4.4K |
2.4M |
41 |
04/11/19 |
04/11/19 |
ASX - By Stock
|
4.4K
|
2.4M
|
41
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading - 2019
|
|
otherperspective
|
4.4K |
2.4M |
29 |
25/10/19 |
25/10/19 |
ASX - By Stock
|
4.4K
|
2.4M
|
29
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading - 2019
|
|
otherperspective
|
4.4K |
2.4M |
17 |
21/10/19 |
21/10/19 |
ASX - By Stock
|
4.4K
|
2.4M
|
17
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading - 2019
|
|
otherperspective
|
4.4K |
2.4M |
19 |
21/10/19 |
21/10/19 |
ASX - By Stock
|
4.4K
|
2.4M
|
19
|
|
ASX - By Stock
|
MSB |
Re:
Ann: MSB and Lonza Enter GVHD Commercial Manufacturing Agreement
|
|
otherperspective
|
193 |
102K |
42 |
17/10/19 |
17/10/19 |
ASX - By Stock
|
193
|
102K
|
42
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading - 2019
|
|
otherperspective
|
4.4K |
2.4M |
39 |
14/10/19 |
14/10/19 |
ASX - By Stock
|
4.4K
|
2.4M
|
39
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading - 2019
|
|
otherperspective
|
4.4K |
2.4M |
47 |
08/10/19 |
08/10/19 |
ASX - By Stock
|
4.4K
|
2.4M
|
47
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
otherperspective
|
275 |
160K |
47 |
07/10/19 |
07/10/19 |
ASX - By Stock
|
275
|
160K
|
47
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Raises A$75 Million
|
|
otherperspective
|
115 |
68K |
47 |
03/10/19 |
03/10/19 |
ASX - By Stock
|
115
|
68K
|
47
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading - 2019
|
|
otherperspective
|
4.4K |
2.4M |
77 |
24/09/19 |
24/09/19 |
ASX - By Stock
|
4.4K
|
2.4M
|
77
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading - 2019
|
|
otherperspective
|
4.4K |
2.4M |
85 |
19/09/19 |
19/09/19 |
ASX - By Stock
|
4.4K
|
2.4M
|
85
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Grunenthal and MSB Enter Strategic Partnership for Back Pain
|
|
otherperspective
|
162 |
85K |
25 |
12/09/19 |
12/09/19 |
ASX - By Stock
|
162
|
85K
|
25
|
|